Annexon (ANNX) to Release Earnings on Monday

Key Points

• Annexon (NASDAQ:ANNX) is expected to report its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.36) per share for the quarter.
• The company's stock recently increased by 1.4%, reaching $2.49, and has a market cap of approximately $272.64 million.
• Several institutional investors have significantly increased their positions in Annexon, with AQR Capital Management boosting its stake by 122.6% in the first quarter.

Annexon (NASDAQ:ANNX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annexon Trading Down 0.4%

Annexon stock traded down $0.01 during mid-day trading on Friday, hitting $2.36. The stock had a trading volume of 1,103,273 shares, compared to its average volume of 1,229,586. The firm has a market capitalization of $258.92 million, a P/E ratio of -2.00 and a beta of 1.30. The firm's 50 day moving average is $2.50 and its 200 day moving average is $2.43. Annexon has a one year low of $1.28 and a one year high of $7.85.

Analyst Ratings Changes

Several research analysts recently weighed in on ANNX shares. Needham & Company LLC dropped their target price on shares of Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright dropped their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Annexon by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company's stock valued at $5,484,000 after purchasing an additional 39,763 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Annexon by 31.1% during the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company's stock valued at $393,000 after buying an additional 48,345 shares in the last quarter. Jane Street Group LLC raised its position in shares of Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock valued at $193,000 after buying an additional 7,553 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Annexon by 122.6% during the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company's stock valued at $142,000 after buying an additional 40,637 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.